It's an Exciting Time for Mantle Cell Lymphoma

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Breyanzi has reportedly shown promising effects for patients with relapsed or refractory follicular lymphoma and B-cell non-Hodgkin lymphoma.

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

The Food and Drug Administration approved Jaypirca for patients with relapsed/refractory mantle cell lymphoma who have been previously treated with multiple lines of therapy.